CELYAD SA/ADR (NASDAQ:CYAD) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of CELYAD SA/ADR (NASDAQ:CYAD) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

Other equities research analysts also recently issued reports about the stock. HC Wainwright reiterated a buy rating and set a $48.00 price objective (down from $52.00) on shares of CELYAD SA/ADR in a research note on Friday, July 5th. Piper Jaffray Companies set a $76.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a research note on Friday, July 5th. Finally, William Blair reiterated a buy rating on shares of CELYAD SA/ADR in a research note on Monday, May 13th.

CELYAD SA/ADR stock opened at $14.40 on Wednesday. CELYAD SA/ADR has a 1 year low of $10.59 and a 1 year high of $32.18. The firm has a 50 day moving average of $15.20. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.02.

An institutional investor recently raised its position in CELYAD SA/ADR stock. Millennium Management LLC grew its holdings in shares of CELYAD SA/ADR (NASDAQ:CYAD) by 69.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,597 shares of the company’s stock after buying an additional 37,171 shares during the quarter. Millennium Management LLC owned 0.92% of CELYAD SA/ADR worth $1,645,000 at the end of the most recent quarter. 7.28% of the stock is owned by institutional investors and hedge funds.

CELYAD SA/ADR Company Profile

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Read More: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on CELYAD SA/ADR (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.